Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Inflammatory cell recruitment, which is potentially mediated by the monocyte chemoattractant protein 1/C-C chemokine receptor type 2 (CCR2) system and by C-C chemokine receptor type 5 (CCR5) activity, may play a role in the development and progression of diabetic nephropathy. PF-04634817 is a dual chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy. METHODS: We evaluated the efficacy of PF-04634817 compared with matching placebo for reduction of albuminuria after 12 weeks of treatment in subjects with type 2 diabetes who received standard of care (SOC; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy), in a randomized, double-blind, placebo-controlled, parallel-group phase 2 study. RESULTS: and a baseline urinary albumin-to-creatinine ratio (UACR) of ≥300 mg/g were randomly assigned 3:1 to receive PF-04634817 (150 or 200 mg orally, once daily) or placebo. The primary analysis was Bayesian, with an informative prior for placebo response (equivalent to including an additional 80 subjects in the placebo arm). We observed a placebo-adjusted reduction in UACR of 8.2% (ratio 0.918; 95% credible interval: 0.75-1.09) at week 12 in the PF-04634817 arm. PF-04634817 appeared to be safe and well-tolerated. CONCLUSION: Despite the good safety profile shown by PF-04634817, clinical development for this indication was discontinued in light of the modest efficacy observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036 · cited 1×
“73 m(2)), or both, has increased over 2 decades in proportion to the prevalence of diabetes.(2) The risk of progression to end-stage kidney disease from diabetic nephropathy is higher in patients with macroalbuminuria (UACR >300 mg/g) and doubles for each doubling of baseline proteinuria.”
BackgroundPhosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy
Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050473 · Cited by 65
Self-citation
Cited by
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
Folkersen, L., Gustafsson, S., Wang, Q., Hansen, D. H., Hedman, Å. K., Schork, A., Page, K., Zhernakova, D. V., Wu, Y., Peters, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00287-2 · Cited by 705
Self-citationInnate immunity in diabetic kidney disease
Tang, S. C. W., & Yiu, W. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0234-4 · Cited by 596
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Rayego-Mateos, S., Rodrigues-Diez, R. R., Fernandez-Fernandez, B., Mora-Fernández, C., Marchant, V., Donate-Correa, J., Navarro-González, J. F., Ortiz, A., & Ruiz-Ortega, M. (2023) · Kidney International · doi:10.1016/j.kint.2022.10.030 · Cited by 366
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Metadata
- Authors
- Gale, J. D., Gilbert, S., Blumenthal, S., Elliott, T., Pergola, P. E., Goteti, K., Scheele, W., & Perros-Huguet, C.
- Venue
- Kidney International Reports
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 3
- Issue
- 6
- Pages
- 1316-1327
- ISSN
- 2468-0249 (ISSN-L)
- OpenAlex
- W2885387214
- Cited by
- 50
- References
- 4
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. https://app.cochat.ai/papers/10.1016/j.ekir.2018.07.010
- The paper
- Gale, J. D., Gilbert, S., Blumenthal, S., Elliott, T., Pergola, P. E., Goteti, K., Scheele, W., & Perros-Huguet, C. (2018). Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. Kidney International Reports. https://doi.org/10.1016/j.ekir.2018.07.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.